Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Incyte Corporation and Merck & Co., Inc.

2019 Year in Review: Clinical Impact of Immunotherapies in the Treatment of Cancer

Release Date: May 15, 2020
Expiration Date: May 15, 2021

Activity Overview

Immunotherapy options for patients with cancer are increasing rapidly, shaping the treatment landscape for patients with a variety of different malignancies.

This online activity features two expert oncologists who will discuss recent advancements in the field of immunotherapy, highlighting noteworthy data presented at major society meetings in 2019. Each module will focus on a different component of immunotherapy and its growing impact in cancer care. Topics will include the exploration of prognostic markers to personalize immunotherapy utilization, current and emerging immunotherapeutic approaches, and the status of clinical trials.

Acknowledgement of Support

This activity is supported by educational grants from Incyte Corporation and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the mechanism of action of immunotherapeutic agents that have been applied to the treatment of patients with cancer
  • Explain the main findings from studies testing novel immunotherapeutic strategies across multiple malignancies
  • Consider current and emerging testing approaches for risk stratification and optimization of immunotherapeutic treatment planning
  • Choose the best strategies to optimize the proactive management of irAEs among patients receiving immunotherapeutic agents

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Primo N. Lara Jr., MD
Primo N. Lara, Jr., MD
Director, University of California Davis Comprehensive Cancer Center
Professor of Medicine
Executive Associate Dean for Cancer Programs
Codman-Radke Endowed Chair for Cancer Research
UC Davis School of Medicine
Deputy Chair
SWOG Cancer Research Network
Sacramento, CA

Disclosures: Primo N. Lara, Jr., MD has no relevant financial relationships with commercial interests.

David F. McDermott, MD
David F. McDermott, MD
Chief, Medical Oncology
Leon V. & Marilyn L. Rosenberg Clinical Cancer Center at Beth Israel Deaconess Medical
Center (BIDMC)
Codirector, Immunotherapy Institute of the Cancer Center at BIDMC
Director, Biologic Therapy and Cutaneous Oncology Programs, BIDMC
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: BMS, Merck, Genentech, Pfizer, Exelixis, X4 Pharma, Alkermes Inc.; Consultant: BMS, Pfizer, Merck, Alkermes Inc., EMD Serono, Eisai, Eli Lilly and Company.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By